Source: Medicines and Medical Devices Safety Authority (NZ) Revision Year: 2022 Publisher: Viatris Ltd, PO Box 11-183, Ellerslie, AUCKLAND www.viatris.co.nz Telephone 0800 168 169
Rytmonorm, 150 mg, film coated tablets.
| Pharmaceutical Form |
|---|
|
Rytmonorm 150 mg – white to off-white, round, biconvex film coated tablets embossed on one face with “150”. The other face is unmarked. |
Each Rytmonorm film coated tablet contains 150 mg of propafenone (as propafenone hydrochloride).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Propafenone |
Propafenone is a class IC anti-arrhythmic agent. It has a stabilising action on myocardial membranes, reduces the fast inward current carried by sodium ions with a reduction in depolarisation rate and prolongs the impulse conduction time in the atrium, AV node and primarily, in the His-Purkinje system. |
| List of Excipients |
|---|
|
Rytmonorm 150 mg tablets also contain: Microcrystalline cellulose |
Blister packs. Pack size of 50 tablets.
Viatris Ltd, PO Box 11-183, Ellerslie, AUCKLAND
www.viatris.co.nz
Telephone 0800 168 169
Date of fisrt approval: 1 October 1992
| Drug | Countries | |
|---|---|---|
| RYTMONORM | Germany, Ecuador, Estonia, Spain, Hong Kong, Croatia, Israel, Italy, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Turkey |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
